In the following video, Motley Fool health-care bureau chief Brenton Flynn discusses one criticism made by Eli Lilly (LLY -3.58%) CEO John Lechleiter of a problem facing big pharmaceutical companies in Europe: Drugs are too cheap. He specifically focuses on how differences in European health-care systems vs. those in the United States mean a lot of pressure to lower prices on pharmaceuticals in Europe, which is damaging to the industry.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Are Drug Prices Too Low?
By Brenton Flynn
–
Mar 7, 2013 at 6:00PM
NYSE: LLY
Eli Lilly
Market Cap
$749B
Today's Change
(-3.58%) -$28.30
Current Price
$761.50
Price as of July 17, 2025, 4:00 p.m. ET
Are pharmaceuticals a steal at these prices?
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Eli Lilly
LLY
$761.50
(-3.58%)
$-28.30
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
3 Underrated Dividend Growth Stocks to Buy and Hold for Years
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
2 Dividend Growth Stocks to Buy and Hold Forever
2 Growth Stocks to Buy Hand Over Fist in July
Which Stock Will Dominate the Weight Management Market Through 2030?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.